AbbVie (ABBV) Other Non-Current Liabilities (2012 - 2026)

AbbVie has disclosed Other Non-Current Liabilities across 15 years of filings, most recently posting $34.1 billion for Q1 2026.

• In Q1 2026, Other Non-Current Liabilities rose 50.18% year-over-year to $34.1 billion; the TTM figure through Mar 2026 stood at $34.1 billion (up 50.18% YoY), while the FY2025 annual figure was $32.6 billion, up 50.32% from the prior year.
• Other Non-Current Liabilities grew to $34.1 billion in Q1 2026, from $32.6 billion in the prior quarter.
• Over the last five years, Other Non-Current Liabilities for ABBV reached as high as $34.1 billion in Q1 2026 and fell as low as $13.8 billion in Q1 2022.
• The 5-year median for Other Non-Current Liabilities is $20.2 billion (2024), against an average of $22.0 billion.
• Annual changes were most pronounced in 2022 — Other Non-Current Liabilities decreased 2.43% — and 2025, when it jumped 51.49%.
• A 5-year view of Other Non-Current Liabilities shows it stood at $16.4 billion in 2022, then rose by 21.4% to $19.9 billion in 2023, then advanced by 8.93% to $21.7 billion in 2024, then jumped by 50.32% to $32.6 billion in 2025, then gained by 4.73% to $34.1 billion in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $34.1 billion, $32.6 billion, and $31.7 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.